330 related articles for article (PubMed ID: 25405658)
1. Rab25 is responsible for phosphoinositide 3-kinase/AKT‑mediated cisplatin resistance in human epithelial ovarian cancer cells.
Fan Y; Wang L; Han X; Liu X; Ma H
Mol Med Rep; 2015 Mar; 11(3):2173-8. PubMed ID: 25405658
[TBL] [Abstract][Full Text] [Related]
2. [Effect of MTRR gene on apoptosis and autophagy pathways in multiresistant epithelial ovarian cancer].
Chen J; Wang Q; Zhang W; Li L
Zhonghua Fu Chan Ke Za Zhi; 2016 Apr; 51(4):285-92. PubMed ID: 27116987
[TBL] [Abstract][Full Text] [Related]
3. miRNA-150 downregulation promotes pertuzumab resistance in ovarian cancer cells via AKT activation.
Wuerkenbieke D; Wang J; Li Y; Ma C
Arch Gynecol Obstet; 2015 Nov; 292(5):1109-16. PubMed ID: 25986891
[TBL] [Abstract][Full Text] [Related]
4. HPIP promotes epithelial-mesenchymal transition and cisplatin resistance in ovarian cancer cells through PI3K/AKT pathway activation.
Bugide S; Gonugunta VK; Penugurti V; Malisetty VL; Vadlamudi RK; Manavathi B
Cell Oncol (Dordr); 2017 Apr; 40(2):133-144. PubMed ID: 28039608
[TBL] [Abstract][Full Text] [Related]
5. Sanguinarine inhibits epithelial ovarian cancer development via regulating long non-coding RNA CASC2-EIF4A3 axis and/or inhibiting NF-κB signaling or PI3K/AKT/mTOR pathway.
Zhang S; Leng T; Zhang Q; Zhao Q; Nie X; Yang L
Biomed Pharmacother; 2018 Jun; 102():302-308. PubMed ID: 29571014
[TBL] [Abstract][Full Text] [Related]
6. 4-Acetylantroquinonol B suppresses autophagic flux and improves cisplatin sensitivity in highly aggressive epithelial cancer through the PI3K/Akt/mTOR/p70S6K signaling pathway.
Liu M; Bamodu OA; Huang WC; Zucha MA; Lin YK; Wu ATH; Huang CC; Lee WH; Yuan CC; Hsiao M; Deng L; Tzeng YM; Yeh CT
Toxicol Appl Pharmacol; 2017 Jun; 325():48-60. PubMed ID: 28408137
[TBL] [Abstract][Full Text] [Related]
7. Downregulation of miR-503 contributes to the development of drug resistance in ovarian cancer by targeting PI3K p85.
Wu D; Lu P; Mi X; Miao J
Arch Gynecol Obstet; 2018 Mar; 297(3):699-707. PubMed ID: 29327155
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of RAB25 expression by RNAi inhibits growth of human epithelial ovarian cancer cells in vitro and in vivo.
Fan Y; Xin XY; Chen BL; Ma X
Pathology; 2006 Dec; 38(6):561-7. PubMed ID: 17393986
[TBL] [Abstract][Full Text] [Related]
9. HOTAIR is a potential target for the treatment of cisplatin‑resistant ovarian cancer.
Wang Y; Wang H; Song T; Zou Y; Jiang J; Fang L; Li P
Mol Med Rep; 2015 Aug; 12(2):2211-6. PubMed ID: 25824616
[TBL] [Abstract][Full Text] [Related]
10. [Effects of PI3K/Akt/NF-κB signal pathway on FSH facilitation on cell proliferation and invasion by human epithelial ovarian cancer].
Xu CL; Lu XL; Yan XN; Wang HL; Chen SQ
Zhonghua Fu Chan Ke Za Zhi; 2012 Feb; 47(2):134-8. PubMed ID: 22455747
[TBL] [Abstract][Full Text] [Related]
11. Wogonin Increases Cisplatin Sensitivity in Ovarian Cancer Cells Through Inhibition of the Phosphatidylinositol 3-Kinase (PI3K)/Akt Pathway.
Xing F; Sun C; Luo N; He Y; Chen M; Ding S; Liu C; Feng L; Cheng Z
Med Sci Monit; 2019 Aug; 25():6007-6014. PubMed ID: 31402794
[TBL] [Abstract][Full Text] [Related]
12. Activation of PI3K/Akt pathway by PTEN reduction and PIK3CA mRNA amplification contributes to cisplatin resistance in an ovarian cancer cell line.
Lee S; Choi EJ; Jin C; Kim DH
Gynecol Oncol; 2005 Apr; 97(1):26-34. PubMed ID: 15790433
[TBL] [Abstract][Full Text] [Related]
13. [Cisplatin resistant effects of dihydrofolate reductase gene expression up-regulation in epithelial ovarian cancer].
Li Z; Wang Q; Zhang W; Yang Z; Li L
Zhonghua Fu Chan Ke Za Zhi; 2015 Nov; 50(11):854-60. PubMed ID: 26887775
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of MACC1 expression increases cisplatin sensitivity in cisplatin-resistant epithelial ovarian cancer cells.
Zhang R; Shi H; Ren F; Li X; Zhang M; Feng W; Jia Y
Oncol Rep; 2016 Apr; 35(4):2466-72. PubMed ID: 26794135
[TBL] [Abstract][Full Text] [Related]
15. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers.
Cheng KW; Lahad JP; Kuo WL; Lapuk A; Yamada K; Auersperg N; Liu J; Smith-McCune K; Lu KH; Fishman D; Gray JW; Mills GB
Nat Med; 2004 Nov; 10(11):1251-6. PubMed ID: 15502842
[TBL] [Abstract][Full Text] [Related]
16. [Combined inhibition of PI3K and MEK has synergistic inhibitory effect on the proliferation of cisplatin-resistant ovarian cancer cells].
Liu Y; Chen X; Luo Z
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2014 Jun; 30(6):592-6. PubMed ID: 24909280
[TBL] [Abstract][Full Text] [Related]
17. BRCA1-IRIS overexpression promotes cisplatin resistance in ovarian cancer cells.
Chock KL; Allison JM; Shimizu Y; ElShamy WM
Cancer Res; 2010 Nov; 70(21):8782-91. PubMed ID: 20940403
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of AKT sensitizes chemoresistant ovarian cancer cells to cisplatin by abrogating S and G2/M arrest.
Zhang D; Piao HL; Li YH; Qiu Q; Li DJ; Du MR; Tsang BK
Exp Mol Pathol; 2016 Jun; 100(3):506-13. PubMed ID: 27163202
[TBL] [Abstract][Full Text] [Related]
19. HOXB4 knockdown enhances the cytotoxic effect of paclitaxel and cisplatin by downregulating ABC transporters in ovarian cancer cells.
Li Y; Sun J; Gao S; Hu H; Xie P
Gene; 2018 Jul; 663():9-16. PubMed ID: 29660518
[TBL] [Abstract][Full Text] [Related]
20. The role of RhoC in ovarian epithelial carcinoma: a marker for carcinogenesis, progression, prognosis, and target therapy.
Zhao Y; Zheng HC; Chen S; Gou WF; Xiao LJ; Niu ZF
Gynecol Oncol; 2013 Sep; 130(3):570-8. PubMed ID: 23764197
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]